Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
15.41
-0.71 (-4.40%)
At close: Aug 28, 2026, 4:00 PM EDT
15.16
-0.25 (-1.62%)
After-hours: Aug 28, 2026, 7:54 PM EDT
Biohaven Earnings Call Transcripts
Fiscal Year 2024
-
Troriluzole demonstrated a 50%-70% reduction in SCA progression over three years, with significant delays in disease decline and reduced fall risk, meeting all primary and secondary endpoints. The therapy was safe, well-tolerated, and is poised for FDA and EMA submissions, potentially becoming the first approved treatment for SCA.